| 0 (0%) | 02-21 17:11 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 5.13  |
1-year : | 5.74 |
| Resists | First : | 4.39 |
Second : | 4.92 |
| Pivot price | 3.84  |
|||
| Supports | First : | 3.53 | Second : | 2.94 |
| MAs | MA(5) : | 3.89 |
MA(20) : | 3.83 |
| MA(100) : | 3.37 |
MA(250) : | 3.88 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 70.4 |
D(3) : | 67.7 |
| RSI | RSI(14): 49.3 |
|||
| 52-week | High : | 7.25 | Low : | 1.85 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ CPIX ] has closed below upper band by 33.7%. Bollinger Bands are 73.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 7 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 3.91 - 3.94 | 3.94 - 3.96 |
| Low: | 3.74 - 3.77 | 3.77 - 3.79 |
| Close: | 3.86 - 3.9 | 3.9 - 3.94 |
Wed, 18 Feb 2026
Medtech Stocks Surge in After-Hours Trading: RxSight, Penumbra, and Evolus Take the Lead - Intellectia AI
Tue, 17 Feb 2026
Cumberland Pharmaceuticals (NASDAQ:CPIX) Stock Passes Above 200 Day Moving Average - Should You Sell? - MarketBeat
Fri, 06 Feb 2026
Cumberland Pharmaceuticals (NASDAQ:CPIX) Stock Passes Above 200-Day Moving Average - Here's Why - MarketBeat
Fri, 06 Feb 2026
Little Excitement Around Cumberland Pharmaceuticals Inc.'s (NASDAQ:CPIX) Revenues As Shares Take 31% Pounding - simplywall.st
Thu, 22 Jan 2026
Cumberland Pharmaceuticals (NASDAQ:CPIX) shareholders are still up 67% over 1 year despite pulling back 10% in the past week - simplywall.st
Sun, 21 Dec 2025
With Cumberland Pharmaceuticals Stock Surging, Have You Considered The Downside? - Trefis
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 15 (M) |
| Shares Float | 9 (M) |
| Held by Insiders | 41.6 (%) |
| Held by Institutions | 23 (%) |
| Shares Short | 101 (K) |
| Shares Short P.Month | 31 (K) |
| EPS | -0.24 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.75 |
| Profit Margin | -8.1 % |
| Operating Margin | -23.8 % |
| Return on Assets (ttm) | -2.9 % |
| Return on Equity (ttm) | -13.3 % |
| Qtrly Rev. Growth | -8.7 % |
| Gross Profit (p.s.) | 2.33 |
| Sales Per Share | 2.75 |
| EBITDA (p.s.) | 0.08 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 7 (M) |
| Levered Free Cash Flow | 6 (M) |
| PE Ratio | -16.25 |
| PEG Ratio | 0 |
| Price to Book value | 2.22 |
| Price to Sales | 1.41 |
| Price to Cash Flow | 8.54 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|